• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Israel·Financial Services·AMDA.TA
Share

Almeda Ventures Limited Partnership Stocks

ILA 244Last Updated 19.10.2026

Issuer Rating

4/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

ILA 151914.88068

ILA 244
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Almeda Ventures Limited Partnership, established in Tel Aviv, Israel, in 2020, functions as a venture capital firm. The partnership strategically deploys capital across various development stages, including seed, startup, early-stage, and established middle-market companies. Its core investment thesis centers on health technology innovation, with a particular emphasis on medical devices, digital health solutions, bio-convergence, and public R&D collaborations. Additionally, Almeda Ventures allocates funds to life sciences research and development enterprises. Geographically, the firm primarily focuses its investments within Israel, the United States, and Europe.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.10.2026 00:09

Moderna's stock plummeted 25% in a single day following a data leak regarding its cancer vaccine

22.10.2026 23:33

"Bullish sentiment evaporated overnight": Nasdaq fell 2.8% and is heading for its worst plunge since June

22.10.2026 22:26

Apple shares have become a "safe haven" amid concerns over AI spending. Should you buy them?

22.10.2026 21:37

Alibaba's stock has fallen the most in two months. What's weighing on it?

22.10.2026 20:57

Revolut has received its first credit rating. S&P anticipates the fintech company's entry into the bond market

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026